Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome

NCT07375524 is registered in ClinicalTrials.gov with Shanghai Escugen Biotechnology Co., Ltd as lead sponsor.

NCT NCT07375524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07375524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome
Lead sponsor
Shanghai Escugen Biotechnology Co., Ltd
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 1, 2026
Completion date
June 30, 2028
Enrollment
40 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

primary sjögren syndrome